

5-Fluorouridine 5'-O-beta-D-galactopyranoside Biochemical

5-Fluorouridine 5'-O-beta-D-galactopyranoside

CATALOG #
AAA227762


PRODUCT SYNONYMS

5-Fluorouridine 5'-O-beta-D-galactopyranoside; WVE-120101; 5-Fluorouridine 5'-O-beta-D-galactopyranoside biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	149965-92-4
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	5-Fluorouridine 5'-O-beta-D-galactopyranoside (5'-O-beta-D-galactosyl-5-fluorouridine) is more than 100x less toxic than 5-Fluorouridine to bone marrow cells in Balb/c mice[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Rovannersen, CAS 2072901-32-5



Structure
Rovannersen, CAS 2072901-32-5

ADDITIONAL INFORMATION

Related Product Information for 5-Fluorouridine 5'-O-beta-D-galactopyranoside biochemical	5-Fluorouridine 5'-O-beta-D-galactopyranoside (5'-O-beta-D-galactosyl-5-fluorouridine) is a 5-Fluorouridine prodrug. 5-Fluorouridine 5'-O-beta-D-galactopyranoside can be converted by the enzyme beta-D-galactosidase to the potent antineoplastic agent 5-Fluorouridine.
References	1. M Meena, et al. Selectivity and Biodistribution of WVE-120101, a Potential Antisense Oligonucleotide Therapy for the Treatment of Huntington's Disease (S56.001). AAN Enterprises. April 18, 2017; 88 (16 Supplement).

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.